DNA Vaccines: Technologies and Global Markets

Jul 2014| BIO067B| BCC Publishing

Report Highlights

The global market for DNA vaccines was valued at $243.7 million in 2013 and is expected to increase to $305.3 million in 2014, and further to $2.7 billion by 2019, a compound annual growth rate (CAGR) of 54.8% over the five-year period from 2014 through 2019.

Report Includes

  • An overview of the global market for DNA vaccines and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Details concerning delivery and synthesis technologies, the forces driving market growth, product formats, and market applications for these products.
  • Information most useful for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefense companies.
  • Comprehensive profiles of leading companies in the field as well as updates to alliance, merger, and acquisition activity.

Report Scope

The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next five years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2014 through 2019 is estimated.

The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing.

We examine DNA synthesis, biotechnology and pharmaceuticals firms, strategic industry alliances, and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies and biodefense, are analyzed, and the main companies in these fields are highlighted.


Covered in This Report Not Covered in This Report
pDNA vaccines—both therapeutic and preventive Viral vector vaccines
pDNA delivery technologies Traditional vaccines

 Source:  BCC Research

Frequently Asked Questions (FAQs)

Analyst Credentials

JON EVANS has been involved in business development and research for the biotechnology industry since 1984. He has been involved in sales, market research and strategy analysis with Fortune 500 clients - with a particular focus on business development challenges and strategies to optimize market performance. He holds a B.S. degree in biology from Rutgers University and MBA in business analysis from San Francisco State University.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: DNA Vaccines: Technologies and Global Markets169Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW6Free
Chapter- 8: C. CRAMER & CO. GMBH50Free
Published - Sep-2009| Analyst - John Bergin| Code - BIO067A

Report Highlights

  • Overall sales in the DNA vaccines market were worth $141 million in 2008, and increased to an estimated $193 million in 2009. By 2014, it is projected to increase substantially to $2.7 billion, for a 5-year compound annual growth rate (CAGR) of 69.5%.
  • The human health vaccine segment was valued at $12 million in 2008. This is expected to increase to nearly $24 million in 2009, and is projected to reach almost $2.3 billion in 2014, for a 5-year CAGR of 149.6%.
  • Sales in the research tools segment amounted to $73 million in 2008, increased to nearly $92 million in 2009, and are projected to reach nearly $166 million in 2014, for a 5-year CAGR of 12.6%.
DNA Vaccines: Technologies and Global Markets

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries